AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.
Evidence
Intellectual Property We own numerous United States and foreign patents and have patent applications pending in the United States and abroad.
Business / Intellectual Property · Filed 24/02/2026
In addition to our patent portfolio, we possess a wide array of unpatented proprietary technology and know-how.
Business / Intellectual Property · Filed 24/02/2026
◦The BioLegend® Human GPI-APD cocktail for WBC with Control Cells uniquely combines a ready-to-use cocktail to identify rare glycosylphosphatidylinositol (GPI)-deficient cell populations with a patented positive control, offering an important tool for paroxysmal nocturnal hemoglobinuria research.
Business / Life Sciences reagents · Filed 24/02/2026
Many of the businesses competing with us in these industries have significant financial and other resources to invest in new technologies, substantial intellectual property portfolios, substantial experience in new product development, regulatory expertise, manufacturing capabilities, and established distribution channels to deliver products to customers.
Risk Factors / Technological competition · Filed 11/08/2026
Third parties have in the past and may in the future also challenge the validity of our issued patents, may circumvent or “design around” our patents and patent applications, or claim that our products, processes or technologies infringe their patents.
Risk Factors / Intellectual property challenges · Filed 11/08/2026
If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage.
Risk Factors / Licensed rights · Filed 11/08/2026
The software constructs process maps for visualization of impurities at each route stage, stores experimental context and expert interpretations, and enables rapid assessment of impurity control effectiveness.
Business / Luminata software · Filed 24/02/2026
The decrease in Life Sciences segment revenue was driven by a decrease in instruments and reagents revenue due to pharmaceutical and biotechnology market headwinds, partially offset by an increase in software revenue from the timing of contract renewals and new orders.
MD&A / Software renewals and new orders · Filed 25/02/2025
The deferred revenue balance is primarily related to the Company’s software as a service offerings, maintenance contracts and prepaid storage arrangements.
Revenue recognition / Deferred revenue arrangements · Filed 11/08/2026
The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.
Revenue recognition / Noncancelable obligations · Filed 11/08/2026
The Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less.
Revenue recognition / Short-duration disclosure exemption · Filed 11/08/2026
The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company.
Revenue recognition / Remaining obligations · Filed 11/08/2026
Our consolidated gross margins decreased 411 basis points in fiscal year 2023, as compared to fiscal year 2022, primarily due to lower revenue from COVID-19 product offerings, and an unfavorable shift in product mix, partially offset by pricing actions.
MD&A / Fiscal 2023 gross margin and pricing · Filed 27/02/2024
Our consolidated gross margin decreased 16 basis points in fiscal year 2024, as compared to fiscal year 2023, primarily due to an unfavorable shift in product mix and higher product costs, partially offset by pricing actions and productivity initiatives.
MD&A / Fiscal 2024 gross margin and pricing · Filed 25/02/2025
Tariffs implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million and reduced our gross margin by approximately $20 million, primarily affecting products manufactured in Europe for the U.S.
Risk Factors / Realized fiscal 2025 tariff costs · Filed 24/02/2026
market. Our comprehensive mitigation strategy included manufacturing optimization, supplier collaboration, selective pricing adjustments, and targeted temporary cost measures to minimize ongoing financial exposure.
MD&A / Fiscal 2025 mitigation and selective pricing · Filed 24/02/2026
Our consolidated operating margin decreased 10 basis points in fiscal year 2025, as compared to fiscal year 2024, due to gross margin headwinds, as discussed above, partially offset by productivity and cost containment initiatives.
MD&A / Fiscal 2025 operating margin · Filed 24/02/2026
Segment operating margin decreased 194 basis points to 24.2% in fiscal year 2025, as compared to 26.1% in fiscal year 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift due to China diagnostic testing policy changes.
MD&A / Diagnostics margin and China policy changes · Filed 24/02/2026
As a percentage of revenue, cost of revenue decreased to 44.2% for the six months ended July 5, 2026, from 44.5% for the six months ended June 29, 2025, resulting in an increase in gross margin of 40 basis points to 55.8% for the six months ended July 5, 2026, from 55.5% for the six months ended June 29, 2025, primarily due to tariff refunds and product mix shift.
MD&A / First-half 2026 gross margin · Filed 11/08/2026
GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related refunds), as compared to $91 million for the same period a year ago.
Second-quarter 2026 reported operating income and refunds · Filed 04/08/2026
Prices are subject to adjustment on account of specifications, quantities, raw materials, cost of production, shipment arrangements
Canadian sales terms / Section 5 price adjustments; retrieved October 19, 2026 · Retrieved 19/10/2026
Operating Activities. Net cash provided by operating activities of our continuing operations was $317.8 million for the six months ended July 5, 2026, as compared to $268.4 million for the six months ended June 29, 2025, an increase of $49.4 million.
Liquidity / First-half 2026 operating cash · Filed 11/08/2026
During the six months ended July 5, 2026, net cash used for capital expenditures was $30.8 million, as compared to $34.9 million for the six months ended June 29, 2025.
Liquidity / First-half 2026 capital expenditures · Filed 11/08/2026
During the six months ended July 5, 2026, we repurchased shares of our common stock for a total cost of $102.5 million, as compared to $447.5 million in the prior year period.
Liquidity / First-half 2026 cash repurchases · Filed 11/08/2026
(“ACD/Labs”) for $72.0 million in cash paid at closing and up to $8.0 million in contingent consideration to be paid in cash based on the achievement of certain revenue metrics through 2028.
Business Combinations / Acquisition consideration · Filed 11/08/2026
Net cash provided by operating activities of continuing operations
181,960
175,467
588,956
664,955
Net cash used in operating activities of discontinued operations
—
(1,237)
(6,023)
(36,656)
Net cash provided by operating activities
181,960
174,230
582,933
628,299
Investing activities:
Capital expenditures
(20,171)
(24,454)
(73,522)
(86,648)
Purchases of investments and notes receivables
(356)
(2,250)
(385)
(6,587)
Proceeds from investments and notes receivables
75
—
75
2,500
Proceeds from U.S.
Cash flow statement / Fiscal 2025 operating cash and capital expenditures · Filed 02/02/2026
Treasury Securities
—
—
—
710,000
Proceeds from disposition of businesses and assets
—
—
229
—
Net cash (used in) provided by investing activities of continuing operations
(20,452)
(26,704)
(73,603)
619,265
Net cash provided by investing activities of discontinued operations
—
9,375
56,250
156,897
Net cash (used in) provided by investing activities
(20,452)
(17,329)
(17,353)
776,162
Financing Activities:
Payments of debt financing costs
—
—
(2,474)
—
Payments of senior unsecured notes
—
—
—
(711,479)
Payments on other credit facilities
(363)
(822)
(521)
(11,593)
Payments for acquisition-related contingent consideration
—
—
(3,838)
(8,832)
Proceeds from issuance of common stock under stock
plans
293
1,528
2,925
7,701
Purchases of common stock
(168,285)
(185,157)
(820,815)
(369,578)
Dividends paid
(7,955)
(8,539)
(32,800)
(34,454)
Net cash used in financing activities of continuing operations
(176,310)
(192,990)
(857,523)
(1,128,235)
Purchases of investments and notes receivables
(356)
(2,250)
(385)
(6,587)
Proceeds from investments and notes receivables
75
—
75
2,500
Proceeds from U.S.
Cash flow statement / Fiscal 2025 repurchases and financing · Filed 02/02/2026
Half (50%) of the long-term incentive compensation granted to our named executive officers in fiscal 2025 will vest based solely upon the achievement of financial performance metrics.
Executive Compensation / Granted performance-linked incentives · Filed 16/03/2026
The metrics of our 2025 LTIP program are organic revenue growth, free cash flow conversion, and adjusted operating margin expansion.
Executive Compensation / 2025 LTIP metrics · Filed 16/03/2026
In addition to prohibiting trading while in possession of material non-public information, our Securities Trading Policy prohibits all employees and members of our board from engaging in the following types of transactions with respect to our securities: • engaging in “short” sales and “selling against the box”; or • trading in puts, calls, straddles, options or any other form of derivative securities; or • directly or indirectly engaging in hedging or monetization activities with respect to our securities including through purchases of financial instruments (such as prepaid variable forward contracts, equity swaps, collars and exchange funds) or other transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of our securities.
Securities Trading Policy / Hedging restrictions · Filed 16/03/2026
Singh $ 1,539,000 124 % $ 1,908,360 125 % $ 2,385,450 155 % Maxwell Krakowiak $ 420,000 124 % $ 520,800 115 % $ 598,920 143 % Joel S.
Executive Compensation / Approved individual bonus uplifts · Filed 16/03/2026
For Mr. Goldberg, who was hired prior to certain changes approved by the committee that are described below, a tax gross-up is provided, if necessary, to make him whole for certain excise taxes imposed under the Internal Revenue Code.
Executive Compensation / Legacy excise-tax gross-up · Filed 16/03/2026
Compensation & Benefits; Nominating & Corporate Governance Yes Pascale Witz 59 2017 Founder and President of PWH Advisors Audit; Compensation & Benefits Yes ii Revvity • 2026 Proxy Statement Table of Contents Corporate Governance Highlights The following table summarizes our board structure and key elements of our corporate governance framework: Size of Board Ten Number of Independent Directors Nine Independent Chair Yes Board Self-Evaluation Annual Review of Independence of Board Annual Independent Directors Meet Without Management Present Yes Structure of Board Non-Classified Voting Standard for Election of Directors in Uncontested Elections Majority of Shares Cast Wide Range of Backgrounds, Experiences and Skills Yes Corporate Governance Guidelines Yes Fiscal 2025 Business Highlights We overcame a dynamic market environment throughout 2025, ultimately exceeding our financial targets provided at the beginning of the year.
Corporate Governance Highlights / Board structure · Filed 16/03/2026
• Our By-laws provide for proxy access, which permits shareholders, or a group of up to 20 shareholders, owning 3% or more of our outstanding shares of common stock continuously for at least three years, to nominate and include in our proxy materials nominees for director 82 Revvity • 2026 Proxy Statement Table of Contents constituting up to 20% of the board or two directors, whichever is greater, subject to the requirements set forth in our By-laws.
Corporate governance / Existing proxy access · Filed 16/03/2026
Overview
Our By-laws currently require a 40% ownership threshold to call a special meeting of shareholders, consistent with Chapter 156D of the Massachusetts General Laws (the “Massachusetts Business Corporations Act”).
Special-meeting proposal / Existing threshold at proxy date · Filed 16/03/2026
Consolidated Results of Operations Fiscal Year 2025 Compared to Fiscal Year 2024 Revenue Revenue for fiscal year 2025 was $2,856.1 million, as compared to $2,755.0 million for fiscal year 2024, an increase of $101.1 million, or 4%, which includes an approximate 1% increase in revenue attributable to favorable changes in foreign exchange rates.
MD&A / Fiscal 2025 reported revenue · Filed 24/02/2026
Restructuring and other costs, which are included in the selling, general and administrative expenses in the consolidated statements of operations, by segment were as follows: Three Months Ended Six Months Ended July 5, 2026 June 29, 2025 July 5, 2026 June 29, 2025 (In thousands) Life Sciences $ 5,926 $ 1,917 $ 9,155 $ 4,445 Diagnostics 29,582 9,233 37,136 9,368 Corporate — 53 (108) 629 $ 35,508 $ 11,203 $ 46,183 $ 14,442 The following table summarizes the changes in the Company’s accrued restructuring balance for the six months ended July 5, 2026.
Restructuring / First-half 2026 charges · Filed 11/08/2026
Pro forma revenue decreased 2% and pro forma organic revenue decreased 3% as compared to the same period a year ago.
Second-quarter 2026 / Life Sciences pro forma growth · Filed 04/08/2026
Pro forma revenue increased 12% and pro forma organic revenue increased 11% as compared to the same period a year ago.
Second-quarter 2026 / Diagnostics pro forma growth · Filed 04/08/2026
The Company recently entered into a definitive agreement to divest its Immunodiagnostics business in China (“China IDX”), which represented approximately 6% of the Company’s total revenue in fiscal year 2025.
China Immunodiagnostics / Signed divestiture agreement · Filed 04/08/2026
The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals.
China Immunodiagnostics / Expected closing and conditions · Filed 04/08/2026
We compete on the basis of service level, price, technological innovation, operational efficiency, product differentiation, product availability, quality and reliability.
Business / Bases of competition · Filed 24/02/2026
Deferred revenue totaled $239.8 million at July 5, 2026, of which $174.3 million was included in “Accrued expenses and other current liabilities” and $65.5 million was included in “Deferred taxes and other long-term liabilities” in the condensed consolidated balance sheet.
Revenue recognition / July 2026 deferred revenue · Filed 11/08/2026
Deferred revenue totaled $224.8 million at December 28, 2025, of which $159.3 million was included in “Accrued expenses and other current liabilities” and $65.5 million was included in “Deferred taxes and other long-term liabilities” in the condensed consolidated balance sheet.
Revenue recognition / December 2025 deferred revenue · Filed 11/08/2026
